Skip NavigationSkip to Content
Return Return to Search Results

Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

  1. Author:
    Rapisarda, A.
    Zalek, J.
    Hollingshead, M.
    Braunschweig, T.
    Uranchimeg, B.
    Bonomi, C. A.
    Borgel, S. D.
    Carter, J. P.
    Hewitt, S. M.
    Shoemaker, R. H.
    Melillo, G.

  2. Author Address

    NCI, DTP Tumor Hypoxia Lab, Frederick, MD 21702 USA. Sci Applicat Int Corp Frederick Inc, NCI, Frederick, MD USA. NCI, Dev Therapeut Program, Frederick, MD USA. Adv Technol Ctr, Ctr Canc Res, Lab Pathol, NCI, Bethesda, MD USA Melillo, G, NCI, DTP Tumor Hypoxia Lab, Bldg 432,Room 218, Frederick, MD 21702 USA
    1. Year: 2004
    2. Date: OCT 1
  2. Journal: Cancer Research
    1. 64
    2. 19
    3. Pages: 6845-6848
  4. Type of Article: Article
  1. Abstract:

    We have previously shown that topotecan, a topoisomerase I poison, inhibits hypoxia-inducible factor (HIF)-1alpha protein accumulation by a DNA damage-independent mechanism. Here, we report that daily administration of topotecan inhibits HIF-1alpha protein expression in U251-HRE glioblastoma xenografts. Concomitant with HIF-1alpha inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. These results provide a compelling rationale for testing topotecan in clinical trials to target HIF-1 in cancer patients

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000224292400003

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel